Monitoring liver cancer return after surgery with blood tests
Part of Cancer, Digestive system clinical trials.
This trial tests whether a blood test that tracks circulating tumor cells (CTCs) can help doctors detect early signs of liver cancer returning after surgery. It aims to give patients and their doctors a better way to monitor for recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with early-stage liver cancer (hepatocellular carcinoma) that can be removed surgically.
- You are in good physical condition (ECOG score 0-1) and have normal liver function (Child-Pugh A).
- You have not received any cancer treatment for this liver cancer yet.
- You do not have another type of cancer now or within the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a blood test that looks for leftover cancer DNA (ctDNA) after surgery can predict if your liver cancer will come back. It compares that test result with what doctors find in the removed tumor tissue.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
This trial is studying people with liver cancer (hepatocarcinoma) whose cancer returns (recurs) or never fully goes away (persists) after surgery. It looks at patterns after treatment at a specific study center, which may help guide better care for future patients.
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.